InterMune, Inc. (NASDAQ:ITMN) will unveil its latest earnings on Wednesday, July 27, 2011. InterMune, Inc. is a biotech company, which is focused on developing and commercializing innovative therapies in pulmonology and hepatology.
InterMune, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 61 cents per share, a wider loss from the year earlier quarter net loss of 46 cents. During the past three months, the average estimate has moved down from a loss of 60 cents. Between one and three months ago, the average estimate was unchanged, but has since dropped during the last month.
Past Earnings Performance: The company topped forecasts last quarter after being in line with estimates the quarter prior. In the first quarter, it reported a loss of 57 cents per share versus a mean estimate of 78 cents. Two quarters ago, it reported net loss of 39 cents per share.
Wall St. Revenue Expectations: On average, analysts predict $5.3 million in revenue this quarter, a decline of 9.5% from the year ago quarter. Analysts are forecasting total revenue of $29.8 million for the year, a decline of 88.5% from last year’s revenue of $259.3 million.
Analyst Ratings: Analysts are bullish on this stock with 12 analysts rating it as a buy, one rating it as a sell and none rating it as a hold.
The company’s revenue has now risen for two straight quarters. In first quarter, revenue increased 4.4% to $6.4 million from the year earlier quarter. In the fourth quarter of the last fiscal year, the figure rose 3555.5%.
Competitors to Watch: Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Amgen, Inc. (NASDAQ:AMGN), Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Pharmasset, Inc. (NASDAQ:VRUS) and Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS).
Stock Price Performance: During April 26, 2011 to July 21, 2011, the stock price had fallen $9.65 (-21%) from $46.05 to $36.40. The stock price saw one of its best stretches over the last year between February 9, 2011 and February 16, 2011 when shares rose for six-straight days, rising 5.2% (+$1.89) over that span. It saw one of its worst periods between November 17, 2010 and November 30, 2010 when shares fell for nine-straight days, falling 8.9% (-$1.23) over that span. Shares unchanged year to date.
(Source: Xignite Financials)